A
Amy C. Shurtleff
Researcher at United States Army Medical Research Institute of Infectious Diseases
Publications - 35
Citations - 2760
Amy C. Shurtleff is an academic researcher from United States Army Medical Research Institute of Infectious Diseases. The author has contributed to research in topics: Ebola virus & Filoviridae. The author has an hindex of 18, co-authored 34 publications receiving 2233 citations. Previous affiliations of Amy C. Shurtleff include United States Department of the Army & SRI International.
Papers
More filters
Journal ArticleDOI
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Travis K. Warren,Robert Jordan,Michael K. Lo,Adrian S. Ray,Richard L. Mackman,Veronica Soloveva,Dustin Siegel,Michel Perron,Roy Bannister,Hui Hon Chung,Nate Larson,Robert G. Strickley,Jay Wells,Kelly S. Stuthman,Sean A. Van Tongeren,Nicole L. Garza,Ginger Donnelly,Amy C. Shurtleff,Cary Retterer,Dima N. Gharaibeh,Rouzbeh Zamani,Tara Kenny,Brett P. Eaton,Elizabeth C. Grimes,Lisa S. Welch,Laura Gomba,Catherine L. Wilhelmsen,Donald K. Nichols,Jonathan E. Nuss,Elyse R. Nagle,Jeffrey R. Kugelman,Gustavo Palacios,Edward Doerffler,Sean Neville,Ernest Carra,Michael O. Clarke,Lijun Zhang,Willard Lew,Bruce Ross,Queenie Wang,Kwon Soo Chun,Lydia Wolfe,Darius Babusis,Yeojin Park,Kirsten M. Stray,Iva Trancheva,Joy Y. Feng,Ona Barauskas,Yili Xu,Pamela Wong,Molly R. Braun,Mike Flint,Laura K. McMullan,Shan Shan Chen,Rachel Fearns,S. Swaminathan,Douglas L. Mayers,Christina F. Spiropoulou,William A. Lee,Stuart T. Nichol,Tomas Cihlar,Sina Bavari +61 more
TL;DR: These results show the first substantive post-exposure protection by a small-molecule antiviral compound against EBOV in nonhuman primates, and the broad-spectrum antiviral activity of GS-5734 in vitro against other pathogenic RNA viruses, including filoviruses, arenavirus, and coronavirus suggests the potential for wider medical use.
Journal ArticleDOI
A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents
Peter B. Madrid,Sidharth Chopra,Ian D. Manger,Lynne Gilfillan,Tiffany R. Keepers,Amy C. Shurtleff,Carol E. Green,Lalitha V. Iyer,Holli Hutcheson Dilks,Robert A. Davey,Andrey A. Kolokoltsov,Ricardo Carrion,Jean L. Patterson,Sina Bavari,Rekha G. Panchal,Travis K. Warren,Jay Wells,Walter H. Moos,RaeLyn L. Burke,Mary J. Tanga +19 more
TL;DR: The feasibility of repurposing existing drugs to face novel threats is demonstrated and this represents the first effort to apply this approach to high containment bacteria and viruses.
Journal ArticleDOI
Development of a new vaccine for the prevention of Lassa fever.
Thomas W. Geisbert,Thomas W. Geisbert,Steven J.M. Jones,Steven J.M. Jones,Elizabeth A. Fritz,Amy C. Shurtleff,Joan B. Geisbert,Ryan Liebscher,Allen Grolla,Ute Ströher,Ute Ströher,Lisa Fernando,Kathleen M. Daddario,Mary C. Guttieri,Bianca R. Mothé,Tom Larsen,Lisa E. Hensley,Peter B. Jahrling,Heinz Feldmann,Heinz Feldmann +19 more
TL;DR: The data suggest that the Lassa vaccine candidate based on recombinant vesicular stomatitis virus is safe and highly efficacious in a relevant animal model that faithfully reproduces human disease.
Journal ArticleDOI
Evaluation of Ebola Virus Inhibitors for Drug Repurposing.
Peter B. Madrid,Rekha G. Panchal,Travis K. Warren,Amy C. Shurtleff,Aaron N. Endsley,Carol E. Green,Andrey A. Kolokoltsov,Robert A. Davey,Ian D. Manger,Lynne Gilfillan,Sina Bavari,Mary J. Tanga +11 more
TL;DR: The results show the benefits and specific challenges associated with drug repurposing and highlight the need for careful evaluation of approved drugs as rapidly deployable countermeasures against future pandemics.
Journal ArticleDOI
Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus
Kristin Spik,Amy C. Shurtleff,Anita K. McElroy,Mary C. Guttieri,Jay W. Hooper,Connie S. Schmaljohn +5 more
TL;DR: Although in general, the HTNV and CCHFV DNA vaccines were not very immunogenic in mice, there were no major differences in performance when given alone or in combination with the other vaccines.